2025 Q4 -tulosraportti
99 päivää sitten
‧29 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 14.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 päivää sittenI wonder why they bother to show 4.5 million shares on the offer side. There is NO momentum in the stock - before new and relevant info comes to the market.- ·18.6.Remember, online event at 10 today - link is in "Today's stock news".I think it's approved - good to have a clarification that the decision is enforceable against the counterparty. A 3-6 month process sounds perhaps a bit optimistic but let's see. If all goes well, Q1-2027 ?
·16.6.That must be said to be really good reading :) Pharma Equity Group wins international arbitration case and is awarded EUR 10,5 mio. plus interest and costs Pharma Equity Group A/S ("PEG" or "the Company") announces that the Company today received a final and binding arbitration award rendered by an international arbitration tribunal under The Danish Institute of Arbitration in the case against Interpatium -- Promoção Imobiliária LDA, Madeira, Portugal ("Interpatium"). The arbitration tribunal has fully upheld PEG's claim and awarded the Company EUR 10,5 mio. plus interest and costs. Interpatium is furthermore ordered to fully pay the costs of the arbitration case. The arbitration tribunal has in its award determined that PEG is entitled to payment of EUR 10,5 mio. from Interpatium -- Promoção Imobiliária LDA as a result of non-payment of the deferred purchase price under the concluded share transfer agreement of 10. January 2019 regarding the sale of shares in Portinho S.A. The arbitration award orders Interpatium to pay: * EUR 10.500.000 * Statutory interest on EUR 10.500.000 from 29. December 2023 until payment occurs * EUR 385.649,54 in arbitration costs * EUR 64.884,84, DKK 1.398.857,30 and USD 1.804,00 in legal costs The arbitration tribunal concluded that: * PEG (formerly Blue Vision A/S) had fulfilled its contractual obligations, including transferring the shares in Portinho S.A. * The agreed purchase price of EUR 10,5 mio. had not been paid. * Interpatium is bound by the share transfer agreement of 10. January 2019. * Interpatium is liable for payment of the purchase price and other obligations under the agreement. The arbitration tribunal simultaneously rejected the counterparty's central objections regarding the validity of the agreement and determined that PEG is entitled to the full claim of EUR 10,5 mio. The arbitration tribunal emphasizes in the award that the decision rests on an independent and thorough assessment of evidence, documentation, and witness statements. Strong confirmation of a significant asset For PEG, the decision represents a significant legal and financial victory after more than two years of work to document and pursue the claim. The award simultaneously establishes an internationally recognized and enforceable legal basis for PEG's claim and underpins the strength of the Company's legal position. The Board of Directors assesses that the award constitutes a significant legal and commercial milestone for the Company. Christian Vinding Thomsen, Chairman of the Board of Directors in Pharma Equity Group A/S, states: "We are very satisfied with the outcome. The award is the result of a persistent effort from management and the Company's advisors. It is particularly positive that the arbitration tribunal has recognized PEG's position on all essential points and awarded the Company the full main claim. This is a decision of great importance for the Company and its shareholders." Next steps PEG will now, in cooperation with its legal advisors, initiate the necessary steps for the recognition and enforcement of the award in the relevant jurisdictions. The Board of Directors will simultaneously assess the accounting implications of the award in connection with upcoming financial reporting. At present, it is not possible to comment on the time horizon for recovery or the final economic effect for the Company. PEG will continuously inform the market about significant developments regarding the enforcement of the award and the recovery of the awarded amounts. For further information, please contact: Christian Vinding Thomsen, Chairman of the Board of Directors in Pharma Equity Group A/S, telephone: +45 2622 7222
I myself am long and a long-term investor, but my impression is that people are waiting for RESULTS. Well, it's a very good partial goal that the lawsuit has been won. Great respect to the management and the lawyers who bravely fought and brought it home. But is the money in the account? No, right? Has a licensing partner been secured yet? No, right? These are the two things that are needed before money comes in. It's probably fine that there's also a focus on medtech, but in the short term, that's hardly where the wealth lies, and Tange himself has also said - which I am happy about as an investor in Reponex for the 11th year - that the focus remains on RNX-011 and -051. Those are what we need to achieve. But the market will not truly react until news that speaks to the above has been delivered. However, this fortunately provides the opportunity to buy in cheaply, if one otherwise believes that the company can deliver.- ·12.6.Re: Portinho - remember the CEO's 2 statements from the presentation of the annual report on 25/3 regarding news in the matter: "Within the next couple of months", "around May". Yes, we can still be "around May" - but why does PEG always have to be late in announcing. If they now expect an announcement much later - then they damn well have to inform the market. For every week that passes without communication - the share price is punished - rightly so. Management's time optimism, and thereafter continual advancement of important KPIs, just creates distrust. Unfortunately, they are starting to have a very good track record for not reaching their KPIs.On June 18th at 10 o'clock, one can ask questions about the recovery process, time horizon, etc. at the HCA online meeting.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
99 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sittenI wonder why they bother to show 4.5 million shares on the offer side. There is NO momentum in the stock - before new and relevant info comes to the market.
- ·18.6.Remember, online event at 10 today - link is in "Today's stock news".I think it's approved - good to have a clarification that the decision is enforceable against the counterparty. A 3-6 month process sounds perhaps a bit optimistic but let's see. If all goes well, Q1-2027 ?
- ·16.6.That must be said to be really good reading :) Pharma Equity Group wins international arbitration case and is awarded EUR 10,5 mio. plus interest and costs Pharma Equity Group A/S ("PEG" or "the Company") announces that the Company today received a final and binding arbitration award rendered by an international arbitration tribunal under The Danish Institute of Arbitration in the case against Interpatium -- Promoção Imobiliária LDA, Madeira, Portugal ("Interpatium"). The arbitration tribunal has fully upheld PEG's claim and awarded the Company EUR 10,5 mio. plus interest and costs. Interpatium is furthermore ordered to fully pay the costs of the arbitration case. The arbitration tribunal has in its award determined that PEG is entitled to payment of EUR 10,5 mio. from Interpatium -- Promoção Imobiliária LDA as a result of non-payment of the deferred purchase price under the concluded share transfer agreement of 10. January 2019 regarding the sale of shares in Portinho S.A. The arbitration award orders Interpatium to pay: * EUR 10.500.000 * Statutory interest on EUR 10.500.000 from 29. December 2023 until payment occurs * EUR 385.649,54 in arbitration costs * EUR 64.884,84, DKK 1.398.857,30 and USD 1.804,00 in legal costs The arbitration tribunal concluded that: * PEG (formerly Blue Vision A/S) had fulfilled its contractual obligations, including transferring the shares in Portinho S.A. * The agreed purchase price of EUR 10,5 mio. had not been paid. * Interpatium is bound by the share transfer agreement of 10. January 2019. * Interpatium is liable for payment of the purchase price and other obligations under the agreement. The arbitration tribunal simultaneously rejected the counterparty's central objections regarding the validity of the agreement and determined that PEG is entitled to the full claim of EUR 10,5 mio. The arbitration tribunal emphasizes in the award that the decision rests on an independent and thorough assessment of evidence, documentation, and witness statements. Strong confirmation of a significant asset For PEG, the decision represents a significant legal and financial victory after more than two years of work to document and pursue the claim. The award simultaneously establishes an internationally recognized and enforceable legal basis for PEG's claim and underpins the strength of the Company's legal position. The Board of Directors assesses that the award constitutes a significant legal and commercial milestone for the Company. Christian Vinding Thomsen, Chairman of the Board of Directors in Pharma Equity Group A/S, states: "We are very satisfied with the outcome. The award is the result of a persistent effort from management and the Company's advisors. It is particularly positive that the arbitration tribunal has recognized PEG's position on all essential points and awarded the Company the full main claim. This is a decision of great importance for the Company and its shareholders." Next steps PEG will now, in cooperation with its legal advisors, initiate the necessary steps for the recognition and enforcement of the award in the relevant jurisdictions. The Board of Directors will simultaneously assess the accounting implications of the award in connection with upcoming financial reporting. At present, it is not possible to comment on the time horizon for recovery or the final economic effect for the Company. PEG will continuously inform the market about significant developments regarding the enforcement of the award and the recovery of the awarded amounts. For further information, please contact: Christian Vinding Thomsen, Chairman of the Board of Directors in Pharma Equity Group A/S, telephone: +45 2622 7222I myself am long and a long-term investor, but my impression is that people are waiting for RESULTS. Well, it's a very good partial goal that the lawsuit has been won. Great respect to the management and the lawyers who bravely fought and brought it home. But is the money in the account? No, right? Has a licensing partner been secured yet? No, right? These are the two things that are needed before money comes in. It's probably fine that there's also a focus on medtech, but in the short term, that's hardly where the wealth lies, and Tange himself has also said - which I am happy about as an investor in Reponex for the 11th year - that the focus remains on RNX-011 and -051. Those are what we need to achieve. But the market will not truly react until news that speaks to the above has been delivered. However, this fortunately provides the opportunity to buy in cheaply, if one otherwise believes that the company can deliver.
- ·12.6.Re: Portinho - remember the CEO's 2 statements from the presentation of the annual report on 25/3 regarding news in the matter: "Within the next couple of months", "around May". Yes, we can still be "around May" - but why does PEG always have to be late in announcing. If they now expect an announcement much later - then they damn well have to inform the market. For every week that passes without communication - the share price is punished - rightly so. Management's time optimism, and thereafter continual advancement of important KPIs, just creates distrust. Unfortunately, they are starting to have a very good track record for not reaching their KPIs.On June 18th at 10 o'clock, one can ask questions about the recovery process, time horizon, etc. at the HCA online meeting.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 14.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
99 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 14.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sittenI wonder why they bother to show 4.5 million shares on the offer side. There is NO momentum in the stock - before new and relevant info comes to the market.
- ·18.6.Remember, online event at 10 today - link is in "Today's stock news".I think it's approved - good to have a clarification that the decision is enforceable against the counterparty. A 3-6 month process sounds perhaps a bit optimistic but let's see. If all goes well, Q1-2027 ?
- ·16.6.That must be said to be really good reading :) Pharma Equity Group wins international arbitration case and is awarded EUR 10,5 mio. plus interest and costs Pharma Equity Group A/S ("PEG" or "the Company") announces that the Company today received a final and binding arbitration award rendered by an international arbitration tribunal under The Danish Institute of Arbitration in the case against Interpatium -- Promoção Imobiliária LDA, Madeira, Portugal ("Interpatium"). The arbitration tribunal has fully upheld PEG's claim and awarded the Company EUR 10,5 mio. plus interest and costs. Interpatium is furthermore ordered to fully pay the costs of the arbitration case. The arbitration tribunal has in its award determined that PEG is entitled to payment of EUR 10,5 mio. from Interpatium -- Promoção Imobiliária LDA as a result of non-payment of the deferred purchase price under the concluded share transfer agreement of 10. January 2019 regarding the sale of shares in Portinho S.A. The arbitration award orders Interpatium to pay: * EUR 10.500.000 * Statutory interest on EUR 10.500.000 from 29. December 2023 until payment occurs * EUR 385.649,54 in arbitration costs * EUR 64.884,84, DKK 1.398.857,30 and USD 1.804,00 in legal costs The arbitration tribunal concluded that: * PEG (formerly Blue Vision A/S) had fulfilled its contractual obligations, including transferring the shares in Portinho S.A. * The agreed purchase price of EUR 10,5 mio. had not been paid. * Interpatium is bound by the share transfer agreement of 10. January 2019. * Interpatium is liable for payment of the purchase price and other obligations under the agreement. The arbitration tribunal simultaneously rejected the counterparty's central objections regarding the validity of the agreement and determined that PEG is entitled to the full claim of EUR 10,5 mio. The arbitration tribunal emphasizes in the award that the decision rests on an independent and thorough assessment of evidence, documentation, and witness statements. Strong confirmation of a significant asset For PEG, the decision represents a significant legal and financial victory after more than two years of work to document and pursue the claim. The award simultaneously establishes an internationally recognized and enforceable legal basis for PEG's claim and underpins the strength of the Company's legal position. The Board of Directors assesses that the award constitutes a significant legal and commercial milestone for the Company. Christian Vinding Thomsen, Chairman of the Board of Directors in Pharma Equity Group A/S, states: "We are very satisfied with the outcome. The award is the result of a persistent effort from management and the Company's advisors. It is particularly positive that the arbitration tribunal has recognized PEG's position on all essential points and awarded the Company the full main claim. This is a decision of great importance for the Company and its shareholders." Next steps PEG will now, in cooperation with its legal advisors, initiate the necessary steps for the recognition and enforcement of the award in the relevant jurisdictions. The Board of Directors will simultaneously assess the accounting implications of the award in connection with upcoming financial reporting. At present, it is not possible to comment on the time horizon for recovery or the final economic effect for the Company. PEG will continuously inform the market about significant developments regarding the enforcement of the award and the recovery of the awarded amounts. For further information, please contact: Christian Vinding Thomsen, Chairman of the Board of Directors in Pharma Equity Group A/S, telephone: +45 2622 7222I myself am long and a long-term investor, but my impression is that people are waiting for RESULTS. Well, it's a very good partial goal that the lawsuit has been won. Great respect to the management and the lawyers who bravely fought and brought it home. But is the money in the account? No, right? Has a licensing partner been secured yet? No, right? These are the two things that are needed before money comes in. It's probably fine that there's also a focus on medtech, but in the short term, that's hardly where the wealth lies, and Tange himself has also said - which I am happy about as an investor in Reponex for the 11th year - that the focus remains on RNX-011 and -051. Those are what we need to achieve. But the market will not truly react until news that speaks to the above has been delivered. However, this fortunately provides the opportunity to buy in cheaply, if one otherwise believes that the company can deliver.
- ·12.6.Re: Portinho - remember the CEO's 2 statements from the presentation of the annual report on 25/3 regarding news in the matter: "Within the next couple of months", "around May". Yes, we can still be "around May" - but why does PEG always have to be late in announcing. If they now expect an announcement much later - then they damn well have to inform the market. For every week that passes without communication - the share price is punished - rightly so. Management's time optimism, and thereafter continual advancement of important KPIs, just creates distrust. Unfortunately, they are starting to have a very good track record for not reaching their KPIs.On June 18th at 10 o'clock, one can ask questions about the recovery process, time horizon, etc. at the HCA online meeting.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt